PT  - JOURNAL ARTICLE
AU  - Ana C. Monteiro
AU  - Rajat Suri
AU  - Iheanacho O. Emeruwa
AU  - Robert J. Stretch
AU  - Roxana Y. Cortes-Lopez
AU  - Alexander Sherman
AU  - Catherine C. Lindsay
AU  - Jennifer A. Fulcher
AU  - David Goodman-Meza
AU  - Anil Sapru
AU  - Russell G. Buhr
AU  - Steven Chang
AU  - Tisha Wang
AU  - Nida Qadir
TI  - Obesity and Smoking as Risk Factors for Invasive Mechanical Ventilation in COVID-19 Respiratory Failure: a Retrospective, Observational Cohort Study
AID  - 10.1101/2020.08.12.20173849
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.12.20173849
4099  - http://medrxiv.org/content/early/2020/08/14/2020.08.12.20173849.short
4100  - http://medrxiv.org/content/early/2020/08/14/2020.08.12.20173849.full
AB  - Purpose To describe the trajectory of respiratory failure in COVID-19 and explore factors associated with risk of invasive mechanical ventilation (IMV).Materials and Methods A retrospective, observational cohort study of 112 inpatient adults diagnosed with COVID-19 between March 12 and April 16, 2020. Data were manually extracted from electronic medical records. Multivariable and Univariable regression were used to evaluate association between baseline characteristics, initial serum markers and the outcome of IMV.Results Our cohort had median age of 61 (IQR 45-74) and was 66% male. In-hospital mortality was 6% (7/112). ICU mortality was 12.8% (6/47), and 18% (5/28) for those requiring IMV. Obesity (OR 5.82, CI 1.74-19.48), former (OR 8.06, CI 1.51-43.06) and current smoking status (OR 10.33, CI 1.43-74.67) were associated with IMV after adjusting for age, sex, and high prevalence comorbidities by multivariable analysis. Initial absolute lymphocyte count (OR 0.33, CI 0.11-0.96), procalcitonin (OR 1.27, CI 1.02-1.57), IL-6 (OR 1.17, CI 1.03-1.33), ferritin (OR 1.05, CI 1.005-1.11), LDH (OR 1.57, 95% CI 1.13-2.17) and CRP (OR 1.13, CI 1.06-1.21), were associated with IMV by univariate analysis.Conclusions Obesity, smoking history, and elevated inflammatory markers were associated with increased need for IMV in patients with COVID-19.Competing Interest StatementSYC consults for PureTech on their deupirfenidone in COVID study.Funding StatementThe First Author is funded by the NIH training grant T32 5T32HL072752-1Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCLA IRB #20-000553All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe dataset used for this manuscript will be readily available upon request to the corresponding author.